Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gold you have been predicting the demise of this company for many years. In your posts it is always a matter of months before they run out of useable funds with the prediction that they will leave all the shareholders in the cold.
It has never come to pass now has it.....
Your predictions have ALWAYS been absolutely WRONG!
Why don't you move on.
Gold, your recent extensive assumptions are based on everything existing in a vacuum.
Gold stated," It absolutely proves"
No I don't think that absolutely proves any such thing...
Are you on the board of QuantRX ?
Gold we always knew that a PMA may be required instead of a 510k.
May is a pretty awesome word don't you think?
Hmmm Gold,
You stated, "Half, it is no assumption that Moro was going to use QuantRX to develop the vet POC test. That is a matter of record."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55552276
Yep. Remember when you were convinced no other Universal Markers existed? I would say we are in pretty good company being listed as a Universal Cancer Marker...Wouldn't you?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67676686&txt2find=universal
Gold, Here is a list of some other Universal cancer markers that have done very well in the market.
It just may be that Recaf should be compared to these as equal or better wouldn't you say?
CA 15-3 can be elevated in malignancies other than breast cancer, including lung, pancreatic, ovarian, liver, and colorectal cancers.
The most frequent cancer which causes an increased CEA is cancer of the colon and rectum. Others include cancers of the pancreas, stomach, breast, lung, and certain types of thyroid and ovarian cancer. Benign conditions which can elevate CEA include smoking, infections, inflammatory bowel disease, pancreatitis, cirrhosis of the liver, and some benign tumors in the same organs in which an elevated CEA indicates cancer.
CA-125...70% of people with cirrhosis, 60% of people with pancreatic cancer, and 20%-25% of people with other malignancies have elevated levels of CA-125.
Conditions that could lead to an elevated PSA level in men who don't have prostate cancer include:
Benign prostate enlargement (benign prostatic hyperplasia)
A prostate infection (prostatitis)
Other less common conditions
Gold, I disagree.
There is no reason for false statements to be made. Ultimately the product has to sell itself.
It does Dr. Moro no good to advertise a product falsely while knowing that it will have to be tested for accuracy before it can be sold.
That would be suicide.
Just ask Hungryleon....who made the following statements that conflicted with eachother. When I asked him to clarify which was true he never could respond.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68519068&txt2find=scientist
Hungry,
For clarification, your posts seem to conflict with one another...Which is it?
I'm a scientist and business student
Or
I'm a science and business student
I just want to gather information to decide whether to invest in this stock.
Or
My involvement in this forum was the result of a school assignment to research the effect of PRs and investors' forum in the value of penny stocks.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67645175&txt2find= style='background-color:yellow;'>scientist
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68517566
How do you know that it isn't just Goldseeker responding to himself?
Gold, so then why should the vet send the sample in the mail to Biocurex's office?
Gold sated, "It is obvious that the sales people on the phone do not know what they are selling. The one I spoke with said it was the collection kit only and not the test."
Gold, read what you posted again. After the collection is performed it is mailed to get the results. Therefore the test was not being sold or they could have produced results without mailing the collection kit out.
I do believe the salesperson did know what they were talking about. You just misinterpreted the answer and twisted it for your posting purpose.
Here is your centrifuge post Gold.
"This is not an easy collection method and all the vets I have used send whole blood samples out for normal testing locally. I do not know any local vets who have centrifuge capability."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46538183&txt2find=centrifuge
Genetic Tests to Generate $25 Billion a Year, UnitedHealth Says
By Alex Nussbaum - Mar 12, 2012 12:00 AM ET .LinkedIn Google +1 Print QUEUEQ..Genetic tests may become a $25 billion annual market in the U.S. within a decade, highlighting the need to identify which exams work the best, insurer UnitedHealth Group Inc. (UNH) said.
A majority of the 1,800 DNA tests developed to identify or manage medical conditions still haven’t been studied enough to prove their effectiveness, UnitedHealth, the biggest U.S. insurer by sales, said in a report today. The technology generated $5 billion in 2010, the insurer said, and three to five new tests are being introduced each month.
The projections bode well for diagnostics companies including Genomic Health Inc. (GHDX), Myriad Genetics Inc. (MYGN) and Life Technologies Corp. (LIFE), said Daniel Leonard, a Leerink Swann & Co. analyst in New York. They also raise questions about the effect on consumers, doctors and governments struggling with rising medical bills, UnitedHealth said.
While genetic exams “hold great promise for better health and medical care,” the Minnetonka, Minnesota-based insurer said in the report. “They also pose significant challenges to a system that is increasingly unaffordable.”
The paper, released to coincide with a Washington D.C. conference on gene testing, calls for cheaper, quicker methods to evaluate the quality of the technology, as well as better education for consumers about privacy protections.
The report echoed concerns from a study last week in the New England Journal of Medicine that found cancer screening may be less useful than hoped because of the wide variety of mutations found in tumors. That may explain why some oncology drugs become less effective even when targeted at specific genes, scientists from the U.K. said.
Cancer, Alzheimer’s
Genetic tests can be used to identify cancers, judge a person’s predisposition to Alzheimer’s disease or gauge how well a particular medicine will work in a specific patient.
UnitedHealth, which covers 36 million people in its medical plans, spent about $500 million for genetic exams and molecular diagnostics in 2010, mostly to detect cancers and infectious diseases like HIV, today’s report said.
The national figure may swell to $15 billion to $25 billion in 2021, with annual growth rates of more than 10 percent, the company said. It based the projections on internal claims and government Medicare and Medicaid data. The ultimate number depends on how popular the tests grow, how expensive they get and insurers’ willingness to pay, among other factors.
Illumina (ILMN) Bid
The predictions seem “reasonable” given the field’s past growth, said Leerink Swann’s Leonard, in a telephone interview. Illumina Inc., a San Diego-based gene mapper, drew a $5.7 billion hostile takeover bid from Roche Holding AG (ROG) in January, in a sign of the market’s attractiveness, Leonard said. Two years ago, General Electric Co. (GE) paid $580 million for diagnostic company Clarient Inc.
Industry leaders include Life Technologies, of Carlsbad, California; Myriad, of Salt Lake City; and Genomic Health, of Redwood City, California, Leonard said.
“It’s going to be a very good place for investors to participate” given “the broad need to reduce health care costs,” Leonard said. “If you use these tests, you could forego expensive and toxic therapies or forego surgery.” For older, relatively simple scans like those for newborn screening or infectious disease, there’s usually evidence of what UnitedHealth called “clinical utility” -- an improvement in the delivery or outcome of patient care.
For most tests, that’s not the case, often because of the high cost of evaluating products or the newness of a particular exam. The Food and Drug Administration could help by allowing more flexible clinical trial designs, while insurers could offer incentives by tying payments to the amount of data backing a test, UnitedHealth said.
To contact the reporter on this story: Alex Nussbaum in New York at anussbaum1@bloomberg.net
To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net
No Gold,
That is only your personal interpretation of things intended to muddy the waters for your personal gain.
Gold, Think about what you just stated.
"Dakota, Moro is now using his personal cash to keep BioCurex alive."
Now does that sound like an owner who is trying to screw the investors?
I think not!
This shows his commitment to the company as well as the shareholders.
Oh ..now I get it.
In your eyes there is absolutely no way that the shareholders can win. So therefore you are right and the thousands of shareholders are all wrong.
Wow. You must be very good at what you do.
Gold I believe you are guessing again.
It was very nice of you to at least look forward by a whopping nine months this time. I do believe that is a record. In the past few years you have always thought smaller saying the company was going out of business much quicker. It seems that you have been incorrect in every one of those assumptions though.
Don't you think that as a public company, Biocurex might have a securities lawyer that approves actions before they take place.
Or do they just ask the magic eight ball a question,shake it up and go with the answer...
I would also assume that Biocurex employs auditors that review transactions to verify that they are within their legal boundaries.
You always take the stance that somehow Dr. Moro is out to screw everyone. If that was the case he could have and would have sold his shares long ago. Instead he has stuck with the loyal shareholders.
He has not sold and he continues to strengthen the company. The share value is low but as you will see, when you are sitting on the bottom...the only way to go is up.
By the way,you are now predicting Smithline will own everything? That contradicts your recent so called facts that said Dr. Moro would take everything for himself personally and leave the shareholders holding the bag.
Gosh it is difficult to predict your predictions that have been so wrong for years now.
Brian Druker, the doctor and cancer researcher who helped develop Gleevec, an early gene-based leukemia medicine made by Novartis AG (NOVN) of Switzerland, said the analysis shows the need for “better tools to identify cancer at earlier stages, when it is far less complex.” Druker directs the Knight Cancer Institute at the Oregon Health & Science University in Portland.
Entire story is included in the link below
http://www.bloomberg.com/news/2012-03-07/cancer-scans-may-give-false-picture-of-genes-driving-disease-study-finds.html
I have seen a few of these potential purchases of animal divisions. Ultimately Recaf may end up a product of a large Pharma through one of these purchases...
Bayer Is Said to Consider Making Offer for Pfizer’s Animal-Health Division
http://www.bloomberg.com/news/2012-03-07/bayer-is-said-to-consider-making-offer-for-pfizer-s-animal-health-division.html
Hmmm that's funny...85,000 shares in the buy column and 70,000 in the sell column. What brings you to your conclusion?
We are now also listed on the new products page at Butler Schein Animal Health.
http://www.butlerschein.com/Site/home/products-and-promotions/new-products
BioCurex Wholly Owned Subsidiary, OncoPet Diagnostics, Signs Distribution Agreement With Animal Health International
Animal Health International
Located in Texas & Colorado
Hey Dog...They are in the dairy market as well as the Equestrian market !!
http://www.walcointl.com/
One would believe that a pharma would be interested in a biomarker that can provide real time information showing if a cancer is decreasing during treatment...
The study also showed a significant drop in circulating RECAF for patients after surgery. The drop was most pronounced in those patients with the highest RECAF values before surgery. Samples taken after longer intervals following surgery exhibited the highest drops.
Dr. Ricardo Moro, BioCurex CEO stated, "These results clearly indicate that RECAF is increased in patients with early stages of breast cancer, and that RECAF decreases in those same patients after surgery. If the original cancer produced an excess of RECAF, its recurrence would also produce excessive RECAF and therefore be detectable with our RECAF test. Also, if 90% of early stage cancers are detectable, recurrence in those cases should also be detected early with the resulting benefit for the patient. These results are the first step in demonstrating that our blood test for cancer can be used to monitor therapy and follow-up treated patients for early detection of recurrence."
Gold, Looks to me like the FDA approved another poor Cancer Marker. Biocurex is much better and should fly right through !!!
OBJECTIVE: • To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and = third repeat biopsy session.
PATIENTS AND METHODS: • Patients (n= 127) aged =70 years, with suspicious digital rectal examination (DRE) and/or persistently elevated age-specific total PSA levels (2.5-6.5 ng/mL) and/or suspicious prior histology (atypical small acinar proliferations [ASAPs]= two cores affected by high-grade prostatic intra-epithelial neoplasia [HGPIN]) undergoing either a first, second, or = third repeat biopsy were investigated using a 12- or 24-core biopsy scheme. • PSAV (= three values collected over =12 months) was calculated using the log-slope method. PCA3 scores were assessed using the Progensa assay®. • After stratification according to the number of previous biopsies (first, second and = third), calculation of specificity, positive and negative predictive values (PPV, NPV) and the proportion of avoided unnecessary repeat biopsies (PAB) compared with tPSA at fixed sensitivity thresholds (75, 85 and 95%) were performed. • Finally, accuracy estimates (area under the curve [AUC]) were quantified for each repeat biopsy scenario.
RESULTS: • At repeat biopsy, overall prostate cancer (PCa) detection was 34.6%. • At first repeat biopsy, PCA3 predicted PCa best (AUC = 0.80) and would have avoided 72.2% of repeat biopsies (75% sensitivity) compared with tPSA. • At second repeat biopsy, %fPSA demonstrated the highest accuracy (AUC = 0.82) and would have avoided 66.7% of repeat biopsies (75% sensitivity) compared with tPSA. • At = third repeat biopsy, again %fPSA demonstrated the highest accuracy (AUC = 0.70) and would have avoided 45.0% of repeat biopsies (75% sensitivity) compared with tPSA. • The main limitation of our study resides in its small sample size.CONCLUSIONS: • The findings of the present study promote the concept that the number of previous repeat biopsy sessions strongly influences the performance characteristics of biopsy risk factors. • Total PSA was no significant risk factor in the entire analysis. By contrast, %fPSA performed best at second and = third repeat biopsy. PSAV's diagnostic potential was reserved to patients at second and = third repeat biopsy. • Finally, PCA3 demonstrated the highest diagnostic accuracy and potential to reduce unnecessary biopsies at first repeat biopsy. However, this advantage dissipated at second and = third repeat biopsy.© 2011 THE AUTHORS; BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
http://www.ncbi.nlm.nih.gov/pubmed/21939492
This is pretty interesting.
1. The test does not diagnose cancer.
2. It is used with a very poor cancer diagnostic test (THE DRE)
3. It only states that "It may help reduce biopsies
4. It had a small study 495 people
5. It was APPROVED by the FDA
6. The FDA approval will increase royalty revenues
7. It had a negative predictive value of 90%
8. The clinical study assay only included men who were
9. For use in conjunction with other patient information to aid in the decision recommended for repeat biopsy
This was approved...Why then can't Recaf couple with a simple DRE and get approved also on the basis that it may help reduce biopsies.
FDA APPROVES PROGENSA® PCA3 ASSAY
First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies--
Test May Help Reduce Unnecessary Repeat Prostate Biopsies --
QUEBEC CITY, February 15, 2012 — DiagnoCure, Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, announced today that the US Food and Drug Administration (FDA) has approved Gen-Probe’s (NASDAQ: GPRO) PROGENSA® PCA3 (Prostate Cancer Antigen 3)
assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a
previous negative biopsy.
“We are delighted about this long awaited FDA approval for the PCA3 test, which we believe will greatly improve how physicians decide what interventions to do with men who have had a negative biopsy,” stated Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure. “This is a pivotal achievement for DiagnoCure. We expect it will increase our royalty revenues and will help us keep investing in the development of new and clinically relevant
diagnostic tests for cancer”.
The PROGENSA PCA3 assay is indicated for use in conjunction with other patient information to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on the current standard of care,
before consideration of PROGENSA PCA3 assay results. A negative PROGENSA PCA3 assay result is associated with a decreased likelihood of a positive biopsy. A prostate biopsy is required to diagnose cancer.
Important Safety Information
The PROGENSA PCA3 assay should not be used for men with atypical small acinar proliferation (ASAP) on their
most recent biopsy. Men with ASAP on their most recent biopsy should be treated in accordance with current
medical guidelines.
The clinical study of the PROGENSA PCA3 assay only included men who were recommended for repeat biopsy
.
Therefore, the performance of the assay has not been established in men for whom a repeat biopsy was not already recommended.
FDA approval of the PROGENSA PCA3 assay was based on a clinical study that began in August 2009 and concluded in May 2010.
The study enrolled 495 eligible men at 14 clinical sites. Gen-Probe submitted a Premarket Approval Application (PMA) to the FDA in August 2010.
In the clinical study, the PROGENSA PCA3 had a negative predictive value of 90%, meaning that a negative
PROGENSA PCA3 assay result predicted a negative prostate biopsy 90% of the time.2
About Prostate Cancer and the PROGENSA PCA3 Assay
According to the American Cancer Society (ACS), prostate cancer is the second most common type of cancer found in American men (behind skin cancer), and the second-leading cause of cancer death in men (after lung cancer). One in six American men will get prostate cancer during his lifetime, and one in 36 will die from it.
The ACS estimates that about 241,000 Americans were newly diagnosed with prostate cancer in 2011, and that approximately 34,000 men died from the disease.
PCA3 is a gene that is highly over-expressed in prostate cancers. Following a digital rectal examination, the PCA3 gene can be quantified in urine specimens together with the prostate-specific antigen (PSA) gene to generate a PCA3 score.
Studies have shown that because the PCA3 gene is highly specific for prostate cancer, it predicts the results of repeat biopsies more accurately than traditional serum PSA testing in patients who have had one or more previous negative prostate biopsies.
Data from more than 80 peer-reviewed publications suggest that PCA3 gene testing, when used with other patient information, may help address some of the well-known challenges urologists face, such as identifying prostate cancers while reducing unnecessary repeat biopsies.
Gen-Probe’s PROGENSA PCA3 assay is the first urine-based molecular diagnostic assay to aid in the decision for repeat biopsy. The test has received regulatory approval and is available for sale in the United States, Canada
and the European Union.
DiagnoCure granted Gen-Probe exclusive worldwide diagnostic rights to the PCA3 gene in November 2003.
About DiagnoCure
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic
tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company
launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the
worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company also has a strategic alliance
with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate
cancer test using PCA3, DiagnoCure’s proprietary molecular biomarker. The PROGENSA® PCA3 test is commercialized in Europe under CE mark and is now approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.
Forward-looking statements
This release contains forward-looking statements that involve known and unknown risks, uncertainties and
assumptions that may cause actual results to differ materially from those expected. By their very nature,
forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties,
known and unknown, many of which are beyond DiagnoCure’s control. As a result, investors are cautioned not
to place undue reliance on these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future revenues are based on management
expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in
DiagnoCure’s most recent Annual Information Form under the heading “Risk Factors”. DiagnoCure undertakes
no obligation to publicly update or revise any forward-looking statements contained herein unless required by
the applicable securities laws and regulations.
Gold, I question if you read what was posted?
Gold, I stated no opinion(s) whatsoever about Paulson owning or not owning shares....All I did was post the filings that you are so fond of...You then infered something about me out of thin air???
You might go back and read the post again in the link below.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72211796
Gold you are assuming an awful lot with that statement / question.
Gold stated,"Half full, do you NOT even know the difference between a share of common stock and a warrant?"
Gold stated,"Nowhere in any of the sec filings does it EVER state that Paulson owned any shares at all."
Item 4. Ownership.
(a) Amount beneficially owned: The Paulsons may be deemed to be the beneficial owners of a total of 15,120,000 shares of Issuer Common Stock. The precise owners of these shares is described more specifically in this paragraph. The Paulsons may be deemed to control Paulson Capital Corp. ("PLCC"), which wholly owns Paulson Investment Company, Inc. ("PICI"). The Paulsons control and are the managing partners of the Paulson Family LLC ("LLC"). Through the LLC, the Paulsons indirectly own 0 shares of Issuer Common Stock. The Paulsons collectively own 0 shares of Issuer Common Stock. Chester Paulson directly owns 0 shares of Issuer Common Stock. Jacqueline M. Paulson directly owns 0 shares of Issuer Common Stock. The Paulsons may be deemed to indirectly own 0 shares of Issuer Common Stock and Underwriter Warrants exercisable into 15,120,000 shares of Issuer Common Stock through PICI. PLCC directly owns 0 shares of Issuer Common Stock. Pursuant to SEC Rule 13d-4, the Paulsons expressly disclaim beneficial ownership of the Underwriter Warrants exercisable into 15,120,000 shares of Issuer Common Stock of which PICI is record owner.
(b) Percent of class: As of December 31, 2011, the Issuer had 177,210,464 shares of Issuer Common Stock issued and outstanding, as reported in their 10-Q filed November 14, 2011 (the "Issuer Outstanding Shares"). The Paulsons actual and deemed beneficial ownership of Issuer Common Stock represented approximately 7.8615% of the Issuer Outstanding Shares. PLCC's indirect beneficial ownership of Issuer Common Stock represented approximately 7.8615% of the Issuer Outstanding Shares.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: The Paulsons have sole power to vote or direct the vote of 0 shares. PLCC has sole power to vote or direct the vote of 0 shares.
(ii) Shared power to vote or to direct the vote: The Paulsons have shared power to vote or direct the vote of 15,120,000 shares. PLCC has shared power to vote or direct the vote of 15,120,000 shares.
(iii) Sole power to dispose or to direct the disposition of: The Paulsons have sole power to dispose or direct the disposition of 0 shares. PLCC has sole power to dispose or direct the disposition of 0 shares.
(iv) Shared power to dispose or to direct the disposition of: The Paulsons have shared power to dispose or direct the disposition of 15,120,000 shares. PLCC has shared power to dispose or direct the disposition of 15,120,000 shares.
Item 5. Ownership of Five Percent or Less of a Class
N/A
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
See Item 4(a)
Item 8. Identification and Classification of Members of the Group
N/A
Item 9. Notice of Dissolution of Group
N/A
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
--------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 9, 2012 By: /s/ Chester L.F. Paulson
Name: Chester L.F. Paulson
Title: Individually
Date: February 9, 2012 By: /s/ Jacqueline M. Paulson
Name: Jacqueline M. Paulson
Title: Individually
Date: February 9, 2012 By: /s/ Chester L.F. Paulson
Name: Paulson Capital Corp.
Title: Chairman of the Board
Urine Test for Prostate Cancer OK'd
Wednesday, February 15, 2012 12:42 PM
Canada's DiagnoCure Inc. said it received U.S. regulatory approval for a prostate cancer test that may help avoid unnecessary biopsies, sending its shares to their highest in about 18 months.
"We expect it (the approval) will increase our royalty revenues," said Yves Fradet, chief medical officer of DiagnoCure, which was founded in 1994.
Royalty revenue for the company, which has a market capitalization of about $31 million, was $658,168 in 2011.
The urine-based test — named Progensa PCA3 — will be used with other patient information to help decide on repeat biopsy in men of 50 years or older.
The company said the PCA3 is a gene that is highly over-expressed in prostate cancers — the second most common type of cancer found in American men, according to the American Cancer Society (ACS).
DiagnoCure licensed Progensa to U.S.-based Gen-Probe, a diagnostic test maker, in November 2003.
The ACS estimates about 241,000 Americans were newly diagnosed with prostate cancer in 2011, and about 34,000 men died from the disease.
DiagnoCure marketed its first diagnostic test, for bladder cancer, in Europe in 1998. The product got U.S. approval in 2000.
The company said the PCA3 test will now be available for sale in the United States, Canada, and the European Union.
Shares of the company were up 35 Canadian cents at C$1.06 on Wednesday morning on the Toronto Stock Exchange. They touched a high of C$1.30 earlier in the day.
© 2012 Reuters. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters.
A post from the past...
I refuse to get into the comparison between RECAF and other markers because Gold Seeker has set up a strategy that no matter what you say, he wins: You can either agree with him, in which case he wins, or you can defend universal cancer markers, in which case he will say that there are two other ones to compete with RECAF.
Anything in between is, of coarse, dismissed. If RECAF is better than the other two, then he will bring up ONE study from another marker and ONE study with RECAF to prove the contrary.
He is unable to address the use of RECAF for monitoring and every time he is confronted with that he goes on a tangent. He has also decided to ignore the two reports that allow for early diagnosis of prostate and breast cancer and moreover, he managed to use that as an argument against RECAF, because if you detect cancer 'too early' (!!!) then you cannot tell which ones will end up killing the patient and which ones will not...
He claims that Moro has the power to convince Abbott, Inverness, the two new board members, investors, etc, while he is the one who has been able to slowly modify reality in this forum to the point we are now arguing whether or not it is better to let cancer grow until it proves itself aggressive and malignant..!!! Total nonsense!
Awesome...a $20 dollar trade...
930 shares at .021...I do get tired of the manipulation...
Touché Mr. Goldseeker,
I would assume it might be embarrassing for one to bring up those cancer related items that appear to be so significant on a BB but yet may make one look uneducated in a venue that includes a person truly educated in Chemistry and or of a true scientific nature such as Dr. Stieber, Dr. Moro or anyone else affiliated with the ISOBM .
In light of this you may want to delay your contact previously recommended. It would appear to be a losing proposition for at least one party.
I would never spar with a mind such as those mentioned above concerning Recaf or cancer diagnostics in general. It is evident that any such attempt would be futile, however It is comical to see some attempt it.
In further response to your post,I would never attack any person on this board. I only post as you say facts and my opinions. With your Extensive Research position previously posted, I only wanted to offer you a chance to further educate yourself in lieu of potentially stating unfounded ideas or comments.
I really have no opinion regarding something as simple as a website. They are a dime a dozen and are about as significant as an alias to me.
Maybe you can debate this simple item with others. I am more interested in the science of Recaf and the prospects of a better cancer diagnostic test for those I care about.
Gosh Gold, between you and Hungryleon we now have a Chemist who speaks German, a Foreign Scientist writing a paper on penny stocks who is also a Science major. This board should be Rockin with good solid statistical and chemical science regarding Recaf.
Knowing German as you do, and the fact that you love to read, I am sure you have read all of Dr. Stiebers authored papers concerning cancer diagnostics.
Maybe you could contact Dr. Stieber and set her straight on the causes of cancer and coach her on the proper diagnostical issues regarding current cancer tests.
I would start with your DRE experience, absent the Recommended PSA companion test and let her know how things really work in the field of diagnostics coming from one who has performed EXTENSIVE RESEARCH.
If you could also fill her in on the Scam thing,I think that would Pretty much catch her up on your Expanded knowledge.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72010561
Who knows, she may even ask you to AUTHOR one of her upcoming papers once she becomes familiar with your work? You too could get paid for your knowledge.
Please do keep the board abreast of your findings Gold.
It is amazing what experience one can find on a penny stock BB !
I specifically agree with the last sentence of your post. You seem very knowledgeable on this subject.
In response to your comment, That is actually scheduled to happen Wenn die Hölle zufriert. Thank you for your concern.
May be Dr. Petra Stieber will write a paper on your EXTENSIVE RESEARCH some day?
Gold, that is nonsense.
Gold, you forgot the scenario of the sky falling in which all companies would go chapter 7. This however would eliminate the need to diagnose cancer and all problems would be solved.
How about Recaf sales do well and all of the shareholders make a lot of money. Those who sold early would be left out of the enormous profits . All those shorting the stock lose their shorts.....
Recaf should be delivering the Gold nano particles to the cancer cells for this technology! Here is the phone # Dr. Moro 130 West 8th Street, Erie, PA 16501 • (814) 480-5776
12/27/11 The long-awaited day has arrived! For more than seven years, friends and followers of the late John Kanzius have been waiting for the day that the “Kanzius Cancer-Killing Machine” would be ready and able to test larger laboratory subjects and ultimately humans. The wait is over according to Executive Director of the Research Foundation, Mark Neidig (1978 PHS Grad)!
During a press conference held last week in Erie, Pennsylvania, Marianne Kanzius, John’s surviving spouse and managing partner of Therm Med, announced that GenV of the Kanzius RF Machine was built and ready to ship
GenV is the fifth model of a machine that has been developed as a result of John’s “ah hah” moment that targeted cancer cells could be destroyed using radiowaves. This new machine, which has a testing subject capacity of up to 800 pounds in weight, is destined for our labs in Houston at The University of Texas MD Anderson Cancer Center, where testing will begin next month.
What does this mean for the research and human trials?
This is major breakthrough in the journey to human trials. We have all been waiting for a machine capable of testing/treating a human; now we have that. Research in 2012 will be the most intense ever – more tests, more validations, more researchers, more money – all with the goal of producing credible outcomes, in larger non-human subjects, to present to the FDA. The momentum is building and your donation today will assure the continuum of progress.
Please make your tax-deductible donation now!
Neidig said, “We believe there has to be a better way to treat cancer!” He closed by saying, “Thank you for your continued help; hope can become reality!”
Photo: Explaining the workings of the new GenV are l-r, Mike Nelson (consultant with RedWind Innovations), Marianne Kanzius (managing partner, Therm Med) and Charlie Rutkowski (VP, Industrial Sales and Mfg.)
First Gold, the results of the test are very good wouldn't you agree...
Your question is valid...why do some people prefer diesel engines over gasoline or coal plants over nuclear etc?
It apparently met a need.
The new format is just that....it is new. A known result is safer to use in a study than an unknown when it is to be published. Further, if the results are even better with the new format that allows one to under promise and over deliver.
You can google and find the phone number for Biocurex. They could answer your question better than I.
Gold, plead post the credentials of Petra Stieber. She is very high up on the ladder! I do believe this trumps your words such as Bogus, scam etc.
Petra Stieber has no reason whatsoever to author a paper that is bogus.
You are losing on this one.....you might be better suited posting on your other boards with words like that.
It's not going to work here anymore.
In the present study, we describe a serum recaf radioimmunoassay that can detect the early stages of breast cancer. The test is capable of distinguishing cancer patients from healthy individuals—and from those with benign lesions—with a degree of accuracy so far unattainable with other cancer markers.
These results strongly suggest that the recaf assay could be used for detecting breast cancer in its early stages.
The reliability of a clinical laboratory finding depends upon the reliability of the analytical re- sults on which it is based. As tumour marke[url][/url][tag]insert-text-here findings are intended to be used in particular for monitoring the course of disease, it is essential that the analytical results that un- derpin them be reproducible. Less than 10 % variation between tests (and thus also between batches of the assay concerned) is an absolute prerequisite. Thanks to a high degree of automation, presently used tumour marker assays satisfy this requirement
3.2.1 Assay Reproducibility And Precision
Ten blind samples distributed within the range of measured recaf values were repeatedly tested to determine the intra- and inter-sample variability of the assay. The intra-sample coefficient of variation was =6% and the inter-assay coefficient of variation was <10%.
Because recaf is found in a variety of cancers and in fetal cells (but not in their mature counterparts), the receptor falls within the definition of a wide-spectrum oncofetal antigen with potential for cancer diagnosis, screening, and follow-up.
I see you missed the memo...
RICHMOND, British Columbia, Dec. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX.OB - News) announced today that its wholly owned subsidiary, OncoPet(TM) Diagnostics, Inc., has executed an agreement for the distribution of the OncoPet Sample Collection Kit for canine cancer diagnosis with Butler Schein(TM) Animal Health. Butler Schein Animal Health, a division of Henry Schein (Nasdaq:HSIC - News), is the leading companion animal health distribution company in the U.S.
http://finance.yahoo.com/news/BioCurex-Wholly-Owned-pz-3587178335.html?x=0